Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.

@article{Goellner2011OvercomingTR,
  title={Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.},
  author={Eva M. Goellner and Bradford Grimme and Ashley R Brown and Y Lin and Xiao-Hong Wang and Kelsey F Sugrue and Leah A. Mitchell and Ram N Trivedi and Jiang-bo Tang and Robert William Sobol},
  journal={Cancer research},
  year={2011},
  volume={71 6},
  pages={2308-17}
}
Glioblastoma multiforme (GBM) is a devastating brain tumor with poor prognosis and low median survival time. Standard treatment includes radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ). However, a large percentage of tumors are resistant to the cytotoxic effects of the TMZ-induced DNA lesion O(6)-methylguanine due to elevated expression of the repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) or a defect in the mismatch repair (MMR) pathway. Although a… CONTINUE READING
40 Extracted Citations
52 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 40 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 52 references

Temozolomide. In: Schwab M, editor. Encyclopedia of cancer

  • RW Sobol
  • 2nd ed. Berlin: Springer;
  • 2009
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…